Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33125, USA
Geriatric Research, Education and Clinical Center (GRECC), Miami VA Healthcare System, Miami, FL, USA.
BMJ. 2017 Jan 17;356:i6505. doi: 10.1136/bmj.i6505.
Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.
微血管并发症(视网膜病变、肾病和神经病变)影响着数以亿计的 2 型糖尿病患者。它们通常影响长期或未控制的疾病患者,但也可能在诊断时或尚未确诊的患者中出现。这些并发症的出现和进展可导致视力、肾脏和神经功能丧失、活动能力和认知能力受损、生活质量下降、就业和生产力受限,以及患者和社会的成本增加。如果不加控制或治疗,它们会导致不可逆转的损害,甚至死亡。本篇综述重点关注 2 型糖尿病患者除血糖控制以外的糖尿病微血管并发症的一级和二级预防。讨论的干预措施包括主要组织指南支持的标准护理干预措施,以及过去十年发表的研究支持的其他拟议干预措施。优先考虑高水平的证据来源,如系统评价和大型多中心随机临床试验。在高质量证据不可用的情况下,也纳入了较小的试验。